You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

144 Results
Guidelines and Advice
Status: Archived
ID: 11-2
Version: 2
Oct 2014
Guidelines and Advice
Status: Current
ID: GL-C50-02
Jan 2012
Guidelines and Advice
Status: Current
ID: GL-C50-04-V2
Version: 2
Jan 2009
Guidelines and Advice
Status: In-Review
ID: GL END 3-23
Version: N/A
Oct 2021
Senior Scientist, Acute and Hospital-Based Care, Ontario Health Senior Scientistanna.chiarelli@ontariohealth.ca
Guidelines and Advice
Status: Archived
ID: 4-7
Jun 2012
Guidelines and Advice
Status: Current
ID: GL-C50-34
Aug 2017
Chercheuse principale, Soins aigus et hospitaliers, Santé Ontario Chercheuse principaleanna.chiarelli@ontariohealth.ca
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
fulvestrant,
alpelisib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    azaCITIDine (tablets) - For maintenance therapy in adult patients with AML who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
azaCITIDine (tablets)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2023

Pages